Alexion Buys A Complementary Business With Achillion

 
• By Jessica Merrill

The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.

Two wedding rings in infinity sign. Love concept. Very small depth. - Image
Alexion has found a business match in Achillion • Source: Shutterstock

More from Archive

More from Scrip